Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Cream in Hidradenitis Suppurativa
NCT06958211Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of ruxolitinib cream in hidradenitis suppurativa (HS), sponsored by Incyte. Started Jun 2025; status: active, not recruiting.
02
Drugs
ruxolitinib cream
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06958211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06958211.